Back to news

ARGX rises as investors revisit upcoming Phase 3 autoimmune myositis data presentation

Investivoq PriceTracker

argenx SE (ARGX) is up 6.1% today. Here is some analysis on what might have caused this price movement. ([argenx.com](https://argenx.com/news/2026/press-release-3383399.html?utm_source=openai))

Analysis: The most likely catalyst is renewed investor focus on argenx’s Phase 3 ALKIVIA program after the company said detailed results will be presented as a late-breaking oral session at a major rheumatology meeting in November 2026. This could also reflect growing confidence that VYVGART Hytrulo can expand into another autoimmune indication after the study previously met its primary endpoint. ([argenx.com](https://argenx.com/news/2026/press-release-3383399.html?utm_source=openai))

Details:

  • On October 19, 2026, argenx said new ALKIVIA data in autoimmune myositis will be featured in a late-breaking oral presentation at ACR Convergence 2026. ([argenx.com](https://argenx.com/news/2026/press-release-3383399.html?utm_source=openai))
  • The company had already announced in August 2026 that the Phase 3 ALKIVIA trial met its primary endpoint in the combined immune-mediated necrotizing myopathy and dermatomyositis population. ([argenx.com](https://argenx.com/news/2026/press-release-3345813.html?utm_source=openai))
  • argenx said patients showed improvement as early as Week 4, with benefits sustained through 52 weeks, which may support enthusiasm for a broader commercial opportunity for VYVGART Hytrulo. ([argenx.com](https://argenx.com/news/2026/press-release-3383399.html?utm_source=openai))
  • A recent SEC-filed exhibit also highlighted continuing data presentations across the VYVGART franchise, reinforcing the market’s focus on pipeline momentum. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1697862/000110465926111631/tm2626570d1_ex99-1.htm?utm_source=openai))

    • Sources:

    argenx, SEC, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    Investivoq Alerts
    Receive ARGX Data Alerts
    Get market-moving data, filings, and signals for ARGX in real time.
    Sign Up

    $ARGX Hedge Fund Activity

    We have seen 257 institutional investors add shares of $ARGX stock to their portfolio, and 205 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • PRICE T ROWE ASSOCIATES INC /MD/ removed 696,908 shares (-20.6%) from their portfolio in Q2 2026, for an estimated $646,570,335
    • FMR LLC added 240,418 shares (+4.8%) to their portfolio in Q2 2026, for an estimated $223,052,607
    • BESSEMER GROUP INC added 203,528 shares (+316.8%) to their portfolio in Q2 2026, for an estimated $188,827,172
    • INVESCO LTD. removed 150,707 shares (-25.3%) from their portfolio in Q2 2026, for an estimated $139,821,433
    • BARCLAYS PLC added 128,927 shares (+2344.1%) to their portfolio in Q2 2026, for an estimated $119,614,602
    • FIERA CAPITAL CORP removed 126,775 shares (-58.4%) from their portfolio in Q2 2026, for an estimated $117,618,041
    • WELLINGTON MANAGEMENT GROUP LLP removed 90,909 shares (-8.9%) from their portfolio in Q2 2026, for an estimated $84,342,642

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ARGX Price Targets

    Multiple analysts have issued price targets for $ARGX recently. We have seen 8 analysts offer price targets for $ARGX in the last 6 months, with a median target of $1073.5.

    Here are some recent targets:

    • Luca Issi from RBC Capital set a target price of $945.0 on 07/07/2026
    • Tazeen Ahmad from B of A Securities set a target price of $1088.0 on 07/02/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $940.0 on 06/25/2026
    • Matthew Harrison from Morgan Stanley set a target price of $1180.0 on 06/24/2026
    • David Nierengarten from Wedbush set a target price of $1000.0 on 06/11/2026
    • Derek Archila from Wells Fargo set a target price of $1291.0 on 06/01/2026
    • Gavin Clark-Gartner from Evercore ISI Group set a target price of $1059.0 on 05/15/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.